Baxter International Inc. (NYSE: BAX) recently announced promising initial study data for its candidate, Vero cell-based seasonal influenza vaccine, now undergoing a Phase I/II clinical trial in Europe. The preliminary data indicate that the vaccine induced strong antibody responses and good tolerability in all study populations. The findings were presented by Hartmut J. [click link for full article]
More...